Matinas Biopharma Holdings, Inc.

MTNB Healthcare Biotechnology

In the quarter to June 2026, EPS grew 79.9%, free cash flow grew 9.15% and total debt fell 54.5%, each against the same quarter a year earlier.

2.37 0.05 −2.07%
Market cap
$2.4M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
1/9
Altman Z
−11.93
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.78 2.79 1.32 0.85
Net Debt/EBITDA
3.73 2.69 1.31 0.52
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(3.18) (4.09) (3.75) (4.30)
Book value per Share
17.82 13.23 7.07 4.21
Free Cash Flow
(1.15) (1.49) (1.60) (1.84)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026